Skip to main content
Fig. 1. | BMC Microbiology

Fig. 1.

From: Chlamydia spp. development is differentially altered by treatment with the LpxC inhibitor LPC-011

Fig. 1.

Treatment of C. trachomatis and C. cavaie-infected cells with LPC reveals an aberrant phenotype and differential sensitivity of each species to LPC. a C. trachomatis-infected McCoy cells were treated with either DMSO, or the indicated concentrations of LPC (in μg/ml) for 48 h at which time LOS and Hsp60 were visualized by confocal microscopy. The MEC was calculated to be 1.92 μg/ml. b Same as in (a) except cells were infected with C. caviae and treated with lower concentrations of LPC. The MEC for C. caviae is 0.25 μg/ml. Treatment of LPC on C. caviae infected cells resulted in the formation of aberrant RBs both at, and well below the MEC of drug. c C. trachomatis L2 and C. caviae infected cells were treated with DMSO or the appropriate MEC of LPC and cells were harvested 48 h.p.i. The number of chlamydial-genome copies was calculated by qPCR. Treatment of C. trachomatis L2 with 1.92 LPC μg/mL (MEC) did not result in a reduction of genome copy number compared to mock-treated L2, while treatment of C. caviae with 0.25 μg/mL resulted in 2-log decrease of genome copy number (*, P < 0.05). d EBs from LPC-treated cells infected with either C. trachomatis or C. caviae were determined. Scale bar is 10 μm

Back to article page